>
Switch to:

Corcept Therapeutics 5-Year EBITDA Growth Rate

: 0.00% (As of Dec. 2020)
View and export this data going back to 2004. Start your Free Trial

Corcept Therapeutics's EBITDA per Share for the three months ended in Dec. 2020 was $0.25.

During the past 12 months, Corcept Therapeutics's average EBITDA Per Share Growth Rate was 13.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 35.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Corcept Therapeutics was 119.30% per year. The lowest was -3.00% per year. And the median was 20.90% per year.

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.

Corcept Therapeutics 5-Year EBITDA Growth Rate Distribution

* The bar in red indicates where Corcept Therapeutics's 5-Year EBITDA Growth Rate falls into.


Corcept Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Corcept Therapeutics  (NAS:CORT) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Corcept Therapeutics 5-Year EBITDA Growth Rate Related Terms

Corcept Therapeutics 5-Year EBITDA Growth Rate Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)